Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David N Assis

Showing results (31-40 of 60) with videos related to

Pageof 6
Sort By:
Journal of Pharmaceutical and Biomedical Analysis|November 15, 2025
A liquid biopsy-RNAseq method for monitoring the expression of genes involved in drug disposition: Proof-of-concept application to cholestatic liver diseaseAmit Dahal, Teresa Sierra, Colleen M Hayes, et al.
Journal of Pharmaceutical and Biomedical Analysis|February 3, 2026
Corrigendum to 'A liquid biopsy-RNAseq method for monitoring the expression of genes involved in drug disposition: proof-of-concept application to cholestatic liver disease' [J. Pharm. Biomed. Anal. (2025) 269: 117244]Amit Dahal, Teresa Sierra, Colleen M Hayes, et al.
Hepatology (Baltimore, Md.)|December 19, 2018
Bile-Derived Organoids From Patients With Primary Sclerosing Cholangitis Recapitulate Their Inflammatory Immune ProfileCarol J Soroka, David N Assis, Leina S Alrabadi, et al.
European Journal of Gastroenterology & Hepatology|January 28, 2023
Outcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel diseaseAmr Sayed, David N Assis, Marina G Silveira, et al.
Clinical Pharmacology and Therapeutics|June 2, 2020
Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to UrsodiolNisanne S Ghonem, Adam M Auclair, Christopher L Hemme, et al.
Drug Safety|February 28, 2008
Use of over-the-counter analgesics in patients with chronic liver disease: physicians' recommendationsSimona Rossi, David N Assis, Monica Awsare, et al.
Vaccine|February 17, 2024
Autoimmune hepatitis: Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunisation safety dataSonali Kochhar, David N Assis, Cara Mack, et al.
JHEP Reports : Innovation in Hepatology|February 3, 2025
<i>Quo vadis</i> autoimmune hepatitis? - Summary of the 5<sup>th</sup> international autoimmune hepatitis group research workshop 2024Bastian Engel, David N Assis, Mamatha Bhat, et al.
Hepatology Communications|October 7, 2020
A Systematic Review of Patient-Reported Outcomes in Primary Biliary Cholangitis and Primary Sclerosing CholangitisHannah P Kim, Sarah R Lieber, Michael E Rogers, et al.
Gastroenterology|August 13, 2021
Defining Primary Sclerosing Cholangitis: Results From an International Primary Sclerosing Cholangitis Study Group Consensus ProcessCyriel Y Ponsioen, David N Assis, Kirsten M Boberg, et al.
Pageof 6

Showing results (31-40 of 60) with videos related to

Sort By:
Pageof 6
Journal of Pharmaceutical and Biomedical Analysis|November 15, 2025
A liquid biopsy-RNAseq method for monitoring the expression of genes involved in drug disposition: Proof-of-concept application to cholestatic liver diseaseAmit Dahal, Teresa Sierra, Colleen M Hayes, et al.
Journal of Pharmaceutical and Biomedical Analysis|February 3, 2026
Corrigendum to 'A liquid biopsy-RNAseq method for monitoring the expression of genes involved in drug disposition: proof-of-concept application to cholestatic liver disease' [J. Pharm. Biomed. Anal. (2025) 269: 117244]Amit Dahal, Teresa Sierra, Colleen M Hayes, et al.
Hepatology (Baltimore, Md.)|December 19, 2018
Bile-Derived Organoids From Patients With Primary Sclerosing Cholangitis Recapitulate Their Inflammatory Immune ProfileCarol J Soroka, David N Assis, Leina S Alrabadi, et al.
European Journal of Gastroenterology & Hepatology|January 28, 2023
Outcomes of immunomodulator and advanced therapies for primary sclerosing cholangitis-associated inflammatory bowel diseaseAmr Sayed, David N Assis, Marina G Silveira, et al.
Clinical Pharmacology and Therapeutics|June 2, 2020
Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to UrsodiolNisanne S Ghonem, Adam M Auclair, Christopher L Hemme, et al.
Drug Safety|February 28, 2008
Use of over-the-counter analgesics in patients with chronic liver disease: physicians' recommendationsSimona Rossi, David N Assis, Monica Awsare, et al.
Vaccine|February 17, 2024
Autoimmune hepatitis: Brighton Collaboration case definition and guidelines for data collection, analysis, and presentation of immunisation safety dataSonali Kochhar, David N Assis, Cara Mack, et al.
JHEP Reports : Innovation in Hepatology|February 3, 2025
<i>Quo vadis</i> autoimmune hepatitis? - Summary of the 5<sup>th</sup> international autoimmune hepatitis group research workshop 2024Bastian Engel, David N Assis, Mamatha Bhat, et al.
Hepatology Communications|October 7, 2020
A Systematic Review of Patient-Reported Outcomes in Primary Biliary Cholangitis and Primary Sclerosing CholangitisHannah P Kim, Sarah R Lieber, Michael E Rogers, et al.
Gastroenterology|August 13, 2021
Defining Primary Sclerosing Cholangitis: Results From an International Primary Sclerosing Cholangitis Study Group Consensus ProcessCyriel Y Ponsioen, David N Assis, Kirsten M Boberg, et al.
Pageof 6